Why AbbVie's Booming 2017 Could Continue in 2018
In the words of the legendary James Brown, I feel good.
Early this year, I bought a position in AbbVie (NYSE:ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock.